PowderJect's Losses
from the look-ma-no-needle dept
PowderJect has announced that its losses have doubled and is asking its investors to be patient. Due to the regulatory red tape it seems that the launch of it's lead product, needle-free delivery of lidocaine will be delayed for a year or two more. This isn't particularly unusual for a biomedical company as many are usually faced with approval setbacks. The non-invasive technology they offer is just as appealing now, as it was before and it still has a long patented life ahead of it.Thank you for reading this Techdirt post. With so many things competing for everyone’s attention these days, we really appreciate you giving us your time. We work hard every day to put quality content out there for our community.
Techdirt is one of the few remaining truly independent media outlets. We do not have a giant corporation behind us, and we rely heavily on our community to support us, in an age when advertisers are increasingly uninterested in sponsoring small, independent sites — especially a site like ours that is unwilling to pull punches in its reporting and analysis.
While other websites have resorted to paywalls, registration requirements, and increasingly annoying/intrusive advertising, we have always kept Techdirt open and available to anyone. But in order to continue doing so, we need your support. We offer a variety of ways for our readers to support us, from direct donations to special subscriptions and cool merchandise — and every little bit helps. Thank you.
–The Techdirt Team
Reader Comments
Subscribe: RSS
View by: Time | Thread
Heh heh
Due to the regulatory red tape it seems that the launch of it's lead product, needless delivery of lidocaine will be delayed for a year or two more.
Hey, Ryan, if it's "needless", why are they doing this? Oh, and Ryan, it should be "its" and not "it's". Okay. Be more careful next time. :)
[ link to this | view in chronology ]
Re: Heh heh
[ link to this | view in chronology ]